Low FODMAP Dietary Approach For FGD/IBS. Our Experience. Charlotte McCamphill 19 th February 2015

Similar documents
The long-term impact of the low-fodmap diet for management of irritable bowel syndrome. Dr Miranda Lomer RD.

Diagnosis and Management of Irritable Bowel Syndrome (IBS) For the Primary Care Provider

FODMAPs: Emerging Science and Implications for Practice

FODMAPs: Major role in food sensitivities

The relationship between FODMAP intake and acute gastrointestinal symptoms in adults with IBS A novel analysis using the FAST Diary

Presenter. Irritable Bowel Syndrome. Objectives. Introduction. Rome Criteria. Irritable Bowel Syndrome 2/28/2018

Gut microbiota in IBS and its modification by diet: probiotics, prebiotics and low FODMAP diet

Irritable Bowel Syndrome

Use of Low FODMAP diet in Scotland. Presented by Mairéad Keegan Dietetic Team Lead, Hairmyres Hospital, NHS Lanarkshire

Amy Bernhard, MS, ACSM-CES Dietetic Intern Morrison Chartwell s Dietetic Internship

Inflammatory or Irritable? (the bowel, not the speaker)

A gut health approach to metabolic health.

Clinical guideline Published: 23 February 2008 nice.org.uk/guidance/cg61

Our microbiome: The role of vital gut bacteria, diet, nutrition and obesity

Dr. Melvyn Letier Constantiaberg Mediclinic October 2016

Treat primary. symptoms. Offer general lifestyle advice. Manage IBS according to the dominant symptom. Follow up. Symptoms do not improve

What I will cover today

What to expect? What IBS is and how this manifests as functional symptoms. How IBD creates functional symptoms for individuals in remission

DOWNLOAD OR READ : IRRITABLE BOWEL SYNDROME ONE DISEASE SEVERAL OR NONE PERSPECTIVES IN DIGESTIVE DISEASES VOL 5 PDF EBOOK EPUB MOBI

IBS - Definition. Chronic functional disorder of GI generally characterized by:

New Tests and Treatments for Dyspepsia and Irritable Bowel Syndrome

Irritable Bowel Syndrome. Mustafa Giaffer March 2017

Addendum to NICE guideline CG61, Irritable bowel syndrome in adults

Dietary Interventions for IBS, IBD & Coeliac Disease. Debbie Blissitt Registered Dietitian

What is Irritable Bowel Syndrome (IBS)?

Tenapanor for irritable bowel syndrome with constipation

An Evidence-based Approach to Dietary Treatment of Irritable Bowel Syndrome

Irritable Bowel Syndrome

William D. Chey, MD, FACG. Page 1 of ACG Midwest Regional Postgraduate Course Copyright 2016 American College of Gastroenterology

Irritable Bowel Syndrome Now. George M. Logan, MD Friday, May 5, :35 4:05 PM

Bowel cancer risk in the under 50s. Greg Rubin Professor of General Practice and Primary Care

William D. Chey, MD Professor of Medicine University of Michigan

Refractory IBS-D: An Evidence-Based Approach to Therapy

Irritable Bowel Syndrome (IBS)

Food Choices and Alternative Techniques in Management of IBS: Fad Versus Evidence

Dietitian Connection Webinar: Dietary management of IBS the low FODMAP diet & other adjunct therapies. Presented by Shirley Webber and Dr Jane Varney

GAPS AND FODMAPS

Irritable Bowel Syndrome

Restriction of Dietary Short Chain Carbohydrates may Attenuate Symptoms of Irritable Bowel Syndrome in Athletes Short Review

NW SMS icons. MFLN Intro

Nutrition and IBD. IBD Talk. Presented by. Hannah Price, paediatric dietitian at RHH. Lauren Farquhar, adult dietitian at RHH

CHAPTER 11 Functional Gastrointestinal Disorders (FGID) Mr. Ashok Kumar Dept of Pharmacy Practice SRM College of Pharmacy SRM University

The Roadmap to FODMAP

SUPPLEMENTARY INFORMATION Associated with

The Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders What are functional GI disorders?

The role of FODMAPs in irritable bowel syndrome

Irritable bowel syndrome in adults

The ImmuneCare Guide to. Gluten Sensitivity

Non coeliac gluten sensitivity: Clinical relevance and recommendations for future research

IBS-D: The Role of Pathophysiology in Assessment and Treatment ReachMD Page 1 of 7


The Low FODMAP Diet: The Essential Guide And Cookbook To The Most Effective IBS Diet (Irritable Bowel Syndrome 2) By Daniel Morgan

IBS Irritable Bowel syndrome Therapeutics II PHCL 430

DOWNLOAD OR READ : THE LOW FODMAP DIET FOR BEGINNERS PDF EBOOK EPUB MOBI

I. Identification Presenters: Date: Name of Organization: Goal Statement: Title of Presentation: Audience Description: Physical Set-up: -

Clinical problems related to GI involvement in SSc

Irritable Bowel Disease. Dr. Alexandra Ilnyckyj MD

Technology appraisal guidance Published: 30 August 2017 nice.org.uk/guidance/ta471

Evolving Therapy in Irritable Bowel Syndrome (IBS)

with DIARRHEA (IBS-D)

Bringing the Low FODMAP Diet into your Nutrition Practice

IRRITABLE BOWEL SYNDROME Dr E Lalor, MB ChB, FRCPC 2016 (but written before Rome IV see Gastroenterology, May 2016).

The Secrets of your Irritable Bowel Syndrome (IBS)

Objectives. Pain Types Brief Review. Referred Pain. Chronic/Recurrent Abdominal Pain 1/12/2017. I have no conflicts of interest to disclose

What Is the Low-FODMAP Diet?

Factsheet LINACLOTIDE (Constella ) Irritable Bowel Syndrome constipation predominant (IBS-C)

IBS. Dan Carter, M.D. Institute of Gastroenterology Sheba medical center

Latest research on fibre and gut health

Treatment of IBS - Diet or Drugs?

FODMAPs. Presented by: Joanna Baker Date: 18 th May 2018

Hompes Method. Practitioner Training Level II. Lesson Eight Part 1C SIBO Protocols

GETTING REAL WITH GUT HEALTH

FODMAPS: Presenta(on Overview

4/14/2018 LEARNING OBJECTIVES

Prof. Dr. Mufti Munsurar Rahman Dept. of Medicine Enam Medical College Hospital

Slide #43. Functional Disorders - An Update 11/8/ MA ACP Annual Scientific Meeting. Functional Disorders: An Update

Understanding IRRITABLE BOWEL SYNDROME (IBS)

Dietary fibre: an old concept in new light

Lead team presentation Eluxadoline for treating irritable bowel syndrome with diarrhoea (STA)

Management of Functional Bowel Disorders

Rome III Criteria for IBS. Irritable Bowel Syndrome: What s the Latest? IBS: What s the Latest? Distinguishing IBS-C from CC

Why does my stomach hurt? Exploring irritable bowel syndrome

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

Angie Jefferson Registered Dietitian & Consultant Nutritionist

with Psychological Wellbeing Practitioners (PWPs) Professor Rona Moss-Morris Section of Health Psychology

What s the Latest? Rome III Criteria for IBS

Top 5 Strategies to Relieve IBS

Guideline scope Diverticular disease: diagnosis and management

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 April 2011

The Beginner s Guide To A D.I.Y Low FODMAP Diet

PELVIC PAIN : Gastroenterological Conditions

Inflammatory bowel disease (IBD) is characterized by inflammation

Coeliac disease (CD) and other dietary restrictions- which nutrients are at risk?

The Role of Food in the Functional Gastrointestinal Disorders

Management and Lifestyle Advice for Adults with Irritable Bowel Syndrome Information for Patients

Is Gut-Directed Hypnotherapy An Effective Treatment For Refractory IBS?

Primary Management of Irritable Bowel Syndrome

Biofeedback Therapy A nurse led management service for functional bowel disorders

Clinically proven to quickly relieve symptoms of common gastrointestinal disorders. TERRAGASTRO - Good health starts in the gut

National Institute for Health and Care Excellence Surveillance programme

Transcription:

Low FODMAP Dietary Approach For FGD/IBS Our Experience Charlotte McCamphill 19 th February 2015

CONTENTS What Is IBS What are FODMAPs Service Provision Audit Results Future Work

WHAT IS IBS The Rome III diagnostic criteria defines Irritable bowel syndrome (IBS) as: Recurrent abdominal pain or discomfort at least 3 days per month in the last 3 months associated with one or more of the following: Improvement with defaecation Onset associated with a change in frequency of stool Onset associated with a change in form (appearance) of stool. (Gastroenterology 2006; 130: 1480-1491)

WHAT IS IBS IBS is best viewed as an interaction of important biological and psychosocial factors. Altered motility, visceral hyperalgesia, disturbance of brain-gut interaction, abnormal central processing, autonomic and hormonal event, genetic and environmental factors, post infections sequels, and psychosocial disturbance are variably involved, depending on the individual. (Gastroenterology 2002; 123: 2108-2131).

ECONOMIC CONSEQUENCES 10-15% in industrialised countries NHS spending 45.6 million per year on IBS (Inadomi, 2003). Approximately 12% of all GP visits are due to IBS. Of the disorders seen by Gastroenterologists 35% are for IBS (Russo et al, 1999). 49% of clients had blood tests 47% having imaging and endoscopic procedures 75% of clients using prescription drugs. (Maxion- Bergemann et al, 2006)

EVIDENCE FOR FODMAPS An innovative approach to the treatment of IBS has recently been developed that comprises a reduction in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) in the diet (Barrett & Gibson, 2007; Shepherd et al., 2008). Staudacher et al (2011) found through a UK service evaluation that composite symptom score data showed better overall symptom response in the low FODMAP group (86%) compared to the standard group (49%, P < 0.001. In 2012, Staudacher et al completed the first randomised controlled trial (RCT) of a low FODMAP diet versus controls and found that 68% of clients reported adequate relief of symptoms after 4 weeks, compared to 23% in control. British Dietetic Association (BDA) 2010 developed a professional guidance document on how to achieve successful dietary management of IBS across the UK. The second line of advice refers to advanced dietary interventions to improve symptoms based on dietary fibre, fermentable carbohydrates and probiotics

WHAT ARE FODMAPS FODMAPs are a group of short chain fermentable carbohydrates which are poorly absorbed within the gastrointestinal tract. FRUCTANS POLYOLS GOS They are osmotically active and undergo bacterial fermentation, leading to loose stools and gas production (Barrett et al., 2010; Ong et al., 2010). FRUCTOSE FODMAPS LACTOSE

SERVICE PROVISION Training from September 2012- January 2013 Referrals all received via Dr Graham Morrison Consultant Gastroenterologist Funding initially for 6 months (pilot audit period) February August 2013 Further funding from August 2013 to October 2014

LOCAL CAREPATHWAY Initial Appointment (duration 1.0 hours) Second appointment 8 weeks post initial (duration 45 minutes) Third and Final Appointment 4-8 weeks post second appointment (duration 45 minutes)

Audit Results

ATTENDANCE RATES A total of 16 out of the potential 19 clients were included in the audit data. 94.7% (18/19) at appointment one. 5.6% (1/18) of clients that did attend appointment one, were only seen once as it was not appropriate to proceed further. Attendance at second OPD was 82.4%. However when these clients were contacted via telephone, 2/17 had forgotten about the appointment due to not receiving a reminder letter via central bookings in the post, both agreed to a further 3 rd appointment. 1/17 patients failed to respond to telephone calls and messages and thus were discharged. Potential attendance rate of 94% (16/17) at appointment two. 14/16 had three appointments, thus 88% adherence to the care-pathway.

RESULTS

% Weight loss between 1st and 3rd OPD 8 7 The average BMI at the first appointment (16 clients) was 27.62kg/m². The range was from 21.48kg/m² 37.5kg/m². 6 5 4 3 2 % Weight loss between 1st and 3rd OPD 1 The average BMI at the third appointment (14 clients) was 27.49 kg/m 2. The range was from 21.6 36.2kg/m 2. 0-1 -2 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Average 3.55% weight loss. 1/8 found diet restrictive, 7/8 had reduced snacks

Was CRP Level Checked? Was ESR Level Checked? 16 14 14 14, 88% 12 12, 75% 12 10 10 8 6 4 8 6 4 4, 25% 2 2, 88% 2 0 Yes No 0 Yes No

Subjective question Asked as part of my assessment Clients own perception

Medications Number of Clients who Previously Trialled Taking at 1st Appointment Taking at 2nd Appointment Taking at 3rd Appointment Antispasmodics 6 5 2 2 Laxatives 3 3 2 2 Proton Pump Inhibitors 4 4 4 4 Tricyclics 1 0 0 0 SSRI 0 1 1 1 Anti-Diarrheal 3 5 1 2

Some expressed immediate improvement Others took longer

SYMPTOM EVALUATION REPORT Symptom Improvement Between Appointment one and three(excluding those who reported not having the symptom). The most prominent improvement in symptoms was: 79% improvement in flatulence/wind 79% improvement in bloating/distention 71% improvement in heartburn 64% improvement in incomplete evacuation 64% improvement in the urgency to open bowels 64% improvement in stomach/abdominal gurgling 64% improvement in pain/bloating 57% improvement in tiredness/lethargy 57% improvement in nausea 50% improvement in acid regurgitation 50% improvement in belching/burping

PATIENT SATISFACTION QUESTIONNAIRE AT APPOINTMENT 3 85% improved in bloating 77% flatulence/wind improvement 70% improved in abdominal/discomfort 69% diarrhoea improvement 62% improvement in energy levels 46% improvement in constipation 46% improvement in nausea

OVERALL QUESTION

PATIENT SATISFACTION QUESTIONNAIRE At the 3rd appointment clients involved in the audit made the following comments: I found the written information easy to understand I found the diet easy to follow Overall I am satisfied with the improvement in my symptoms % % % Strongly disagree 1 8% 0 0% 1 8% Disagree 0 0% 0 0% 0 0% Neutral 2 15% 2 15% 2 15% Agree 4 31% 6 46% 5 38% Strongly agree 6 46% 5 39% 5 38%

Was the Client Re-referred back to the Gastro Team by the Dietitian? No 81% Not Recorded 6% Yes 13%

CONCLUSION Job satisfaction! Gastroenterology Support Excellent response rates Need to be appropriate referrals Need dedicated time for each appointment

FUTURE WORK Business Case for further funding Carepathway for GP s for IBS/FGD clients Relook at our carepathway/protocol Regional Care Pathway for FGD Future audits/service evaluation/patient satisfaction questionnaires

Thank You